Literature DB >> 2706634

Formation and elimination of 7-hydroxymethotrexate in the rat in vivo after methotrexate administration.

R M Bremnes1, L Slørdal, E Wist, J Aarbakke.   

Abstract

Bile, urine, and serum concentrations of methotrexate (MTX) and 7-hydroxy-methotrexate (7-OH-MTX) were monitored in rats in vivo following a short-time infusion of 10 mg/kg [3H]MTX. The experiments were performed in one group of anesthetized, bile-drained rats and in two control groups, one anesthetized and one unanesthetized, that were not bile-drained. Peak biliary levels of MTX (3.8 x 10(-3) M) and 7-OH-MTX (1.8 x 10(-4) M) appeared within 15 min after cessation of infusions. For two log ranges of serum MTX concentrations, biliary levels remained 180-fold higher. High bile 7-OH-MTX levels appeared few min after start of MTX administration, and were 720 times higher than the peak serum concentrations, indicating that the liver is a major site of 7-OH-MTX formation in the rat. 7-OH-MTX concentrations in bile declined monophasically with a half-life of 29.4 min, while MTX showed a biphasic elimination with initial and second phase half-lives of 23.1 and 86.4 min, respectively. Bile was the major excretory route for MTX and 7-OH-MTX, with 50% of the dose recovered as the parent compound and 3.6% as the metabolite. There was no difference in urinary recovery of MTX in bile-drained and control animals, indicative of insignificant enterohepatic circulation of MTX. This was further corroborated by the finding of just 2.1% urinary recovery of MTX in rats who received previously collected MTX-containing bile through a duodenal catheter. Serum concentration curves were analyzed according to a three-compartment open model with an initial elimination half-life of 1.7-3.3 min, a second phase half-life of 15.4-21.0 min, and a terminal phase half-life of 119-240 min. Our finding of 7-OH-MTX formation and high biliary levels of the metabolite in the rat, can be used as basis for studies of interactions with in vivo MTX conversion to the 7-hydroxy metabolite.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2706634

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Evaluation of methotrexate tissue exposure by in situ microdialysis in a rat model.

Authors:  O Ekstrøm; A Andersen; D J Warren; K E Giercksky; L Slørdal
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat.

Authors:  E Smeland; R M Bremnes; A Andersen; R Jaeger; T J Eide; N E Huseby; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Inhibition of 7-hydroxymethotrexate formation by amsacrine.

Authors:  R M Bremnes; E Smeland; N P Willassen; E Wist; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  High-dose 7-hydromethotrexate: acute toxicity and lethality in a rat model.

Authors:  E Smeland; O M Fuskevåg; K Nymann; J S Svendesn; R Olsen; S Lindal; R M Bremnes; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

5.  Interactions of vinblastine and vincristine with methotrexate transport in isolated rat hepatocytes.

Authors:  E Smeland; R M Bremnes; A Bessesen; R Jaeger; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Expression levels of multidrug resistance-associated protein 4 (MRP4) in human leukemia and lymphoma cell lines, and the inhibitory effects of the MRP-specific inhibitor MK-571 on methotrexate distribution in rats.

Authors:  Kenji Takeuchi; Masakazu Shibata; Eiji Kashiyama; Ken Umehara
Journal:  Exp Ther Med       Date:  2012-06-29       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.